Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 18/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26616743 | 0.94 | ACHE (0.43) | KIF11 | |
| SCHEMBL16330568 | 0.90 | HDAC3 (0.40) | KIF11 | |
| SCHEMBL17493273 | 0.86 | CA14 (0.41) | KIF11 | |
| SCHEMBL14708941 | 0.84 | CA14 (0.45) | KIF11 | |
| SCHEMBL18291881 | 0.83 | CA14 (0.41) | KIF11 | |
| SCHEMBL16141285 | 0.82 | CA14 (0.45) | KIF11 | |
| SCHEMBL13753316 | 0.82 | KIF11 (0.43) | KIF11 | |
| SCHEMBL12917526 | 0.81 | CA14 (0.39) | KIF11 | |
| SCHEMBL13753391 | 0.81 | KIF11 (0.43) | KIF11 | |
| SCHEMBL14709092 | 0.80 | CA14 (0.38) | KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9561287-B2 | Carrier-linked treprostinil prodrugs | ASCENDIS PHARMA A/S (DK) | 2017-02-07 | — | — | US | disclosed |
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA GMBH (DE) | 2015-03-26 | — | — | US | disclosed |
| US-20140303245-A1 | Sustained Release Composition of Prostacyclin | ASCENDIS PHARMA A/S (DE) | 2014-10-09 | — | — | US | disclosed |
| US-20140296150-A1 | Carrier-Linked Treprostinil Prodrugs | ASCENDIS PHARMA A/S (DK) | 2014-10-02 | — | — | US | disclosed |
| WO-2013024052-A1 | CARRIER-LINKED TREPROSTINIL PRODRUGS | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2013024051-A1 | SUSTAINED RELEASE COMPOSITION OF PROSTACYCLIN | ASCENDIS PHARMA A/S (DK) | 2013-02-21 | — | — | WO | disclosed |
| WO-2011012723-A1 | INJECTABLE SUSTAINED RELEASE COMPOSITIONS COMPRISING A PRAMIPEXOLE PRODRUG | ASCENDIS PHARMA AS (DK) | 2011-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140296150-A1 | Carrier-Linked Treprostinil Prodrugs | PAH, TK1, SLC16A1 | KIF11 1524/4885 |
| US-20140303245-A1 | Sustained Release Composition of Prostacyclin | PTGIR, PTGIS, PTGS1 | KIF11 3742/4885 |
| US-20150087688-A1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ABCB1, CYP2D6, LDHA | KIF11 3923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.